We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Gene Mutations Found For Malignant Brain Tumor

By LabMedica International staff writers
Posted on 23 Aug 2011
Genetic mutations found on chromosomes could increase the chances for an effective combination of drug therapy to treat the second most common type of brain tumor. More...


The primary cancer genes involved in the development of oligodendrogliomas (ODs) were known to be on the chromosomes 1 and 19, but not the particular gene information, which was found using whole genome sequencing technology.

Scientists at Duke University Medical Center (Durham, NC, USA) and Johns Hopkins University (Baltimore, MD, USA) performed exomic sequencing of seven malignant brain tumors. They sequenced the coding exons of 20,687 genes in DNA from the seven anaplastic ODs using the HiSeq platform (Illumina, San Diego, CA, USA).

The investigators found the protein capicua homolog gene (CIC) on chromosome 19 and far upstream element-binding protein 1 gene (FUBP1) on chromosome 1 based on an initial study of seven oligodendrogliomas and uncovered six mutations and two mutations, respectively, in the seven tumors. Further study of 27 more of these tumors showed that there were 12 and 3 mutations of CIC and FUBP1, respectively. The two genes were rarely mutated in other types of cancers, indicating that they are oligodendroglioma-specific genes. The genes they identified are tumor suppressor genes. The cancer-related pathways that involve these genes could become targets for future treatments.

Hai Yan, MD, PhD, co-corresponding author of the study, said, "The team used whole genome sequencing technology so that no genes would be excluded, and we found to our surprise that one gene, on chromosome 19, was mutated in six out of the seven initial tumor specimens we sequenced. A mutation frequency of 85% is very high." Another very important feature is that the genes could be used as biomarkers to distinguish this type of cancer from other types of brain tumors. The study was published on August 4, 2011 in Science.

Related Links:
Duke University Medical Center
Johns Hopkins University
illumina



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Electrolyte Analyzer
BKE-B
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: WashU Medicine researchers found that dozens of blood proteins shift during Alzheimer’s treatment and may help monitor the effects of the medication. (Image Credit: Matt Miller/WashU Medicine)

Blood Biomarker Patterns Could Support Monitoring of Anti-Amyloid Treatment

Patients with early-stage Alzheimer’s disease may receive anti-amyloid therapy to clear amyloid protein deposits from the brain. These treatments can slow disease progression, but they do not cure the... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.